Involvement of neutral sphingomyelinase in the angiotensin II signaling pathway

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 10, 2015, Pages F1178-F1187

  Bautista Pérez, Rocio ^a   Del Valle Mondragón, Leonardo ^a   Cano Martínez, Agustina ^a   Pérez Méndez, Oscar ^a   Escalante, Bruno ^b   Franco, Martha ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Angiotensin II; Cyclooxygenase; Phospholipase A2; Renal vasoconstriction; Sphingomyelinase; Thromboxane A2

Indexed keywords

3,3' (1,4 PHENYLENE)BIS[N [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ACRYLAMIDE]; 5,8,11,14 ICOSATETRAYNOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANGIOTENSIN II; ARACHIDONYL TRIFLUOROMETHYL KETONE; CERAMIDASE; CERAMIDE; CYTOSOLIC PHOSPHOLIPASE A2; FUREGRELATE; INDOMETACIN; N OLEOYLETHANOLAMINE; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOXANE B2; THROMBOXANE SYNTHASE INHIBITOR; ANILINE DERIVATIVE; BENZYLIDENE DERIVATIVE; NSMAF PROTEIN, RAT; PHOSPHOLIPASE A2; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ISOLATED KIDNEY; KIDNEY BLOOD VESSEL; LIPID HYDROLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASOCONSTRICTION; ANIMAL; DRUG EFFECTS; IN VITRO STUDY; KIDNEY; PHYSIOLOGY; WISTAR RAT;

ANGIOTENSIN II; ANILINE COMPOUNDS; ANIMALS; BENZYLIDENE COMPOUNDS; CERAMIDES; IN VITRO TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHOLIPASES A2; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; THROMBOXANE B2; VASOCONSTRICTION;

EID: 84930859391     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00079.2014     Document Type: Article

References (58)

1. 2-induced relaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol 294: H2363–H2370, 2008.
2. Bautista R, Sánchez A, Hernández J, Oyekan A, Escalante B. Angiotensin II type AT2 receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 38: 669–673, 2001.
3. Bautista-Pérez R, Arellano A, Franco M, Osorio H, Coronel I. Enalaprilat-mediated activation of kinin B1 receptors and vasodilation in the rat isolated perfused kidney. Pharmacology 87: 195–203, 2011.
4. Boini KM, Xia M, Li C, Zhang C, Payne LP, Abais JM, Poklis JL, Hylemon PB, Li PL. Acid sphingomyelinase gene deficiency ameliorates the hyperhomocysteinemia-induced glomerular injury in mice. Am J Pathol 179: 2210–2219, 2011.
5. Boini KM, Zhang C, Xia M, Poklis JL, Li PL. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 334: 839–846, 2010.
6. Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest 107: 1339–1345, 2001.
7. Chatziantoniou C, Arendshorst WJ. Angiotensin and thromboxane in genetically hypertensive rats: renal blood flow and receptor studies. Am J Physiol Renal Fluid Electrolyte Physiol 261: F238–F247, 1991.
8. 2]i responses to ANG II. Am J Physiol Renal Physiol 288: F658–F664, 2005.
9. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, Castañeda J, González C, Villamor E, Perez-Vizcaino F. Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 82: 296–302, 2009.
10. Czyborra P, Saxe M, Fetscher C, Meyer Zu Heringdorf D, Herzig S, Jakobs KH, Michel MC, Bischoff A. Transient relaxation of rat mesenteric microvessels by ceramides. Br J Pharmacol 135: 417–426, 2002.
11. Dunn M. The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions. Drugs 33, Suppl 1: 56–66, 1987.
12. 2 mediated effect of angiotensin II in the rabbit isolated perfused kidney. Arch Int Physiol Biochim Biophys 99: 397–400, 1991.
13. 2 signaling in rat afferent arterioles: stimulation of cyclic ADP ribose and IP3 pathways. Am J Physiol Renal Physiol 288: F785–F791, 2005.
14. 2 signaling in afferent arterioles. Am J Physiol Renal Physiol 289: F1012–F1019, 2005.
15. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 531: 38–46, 2002.
16. Ho WS, Barrett DA, Randall MD. ‘Entourage’ effects of N-almitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837–846, 2008.
17. Hsiao SH, Constable PD, Smith GW, Haschek WM. Effects of exogenous sphinganine, sphingosine, and sphingosine-1-phosphate on relaxation and contraction of porcine thoracic aortic and pulmonary arterial rings. Toxicol Sci 86: 194–199, 2005.
18. 2. Biochem Biophys Res Commun 220: 834–838, 1996.
19. 2, and facilitates its membrane docking and arachidonic acid release. FASEB J 15: 7–9, 2001.
20. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 111: 21–34, 2006.
21. 2 concentration. Naunyn Schmiedebergs Arch Pharmacol 372: 242–250, 2005.
22. Johns DG, Jin JS, Wilde DW, Webb RC. Ceramide-induced vasorelaxation: An inhibitory action on protein kinase C. Gen Pharmacol 33: 415–421, 1999.
23. 2-dependent ceramide signaling. Am J Physiol Heart Circ Physiol 275: H1592–H1598, 1998.
24. Kamata K, Hosokawa M, Matsumoto T, Kobayashi T. Altered arachidonic acid-mediated responses in the perfused kidney of the streptozotocin-induced diabetic rat. J Smooth Muscle Res 42: 171–187, 2006.
25. Kleine L, Liu G, Leblanc N, Hébert RL. Bradykinin stimulates ceramide production by activating specific BK-B1 receptor in rat small artery. Am J Physiol Heart Circ Physiol 282: H175–H183, 2002.
26. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251–287, 2007.
27. Leis HJ, Windischhofer W. Inhibition of cyclooxygenases 1 and 2 by the phospholipase-blocker, arachidonyl trifluoromethyl ketone. Br J Pharmacol 155: 731–737, 2008.
28. Li PL, Zhang DX, Zou AP, Campbell WB. Effect of ceramide on KCa channel activity and vascular tone in coronary arteries. Hypertension 33: 1441–1446, 1999.
29. López B, Salom MG, Arregui B, Valero F, Fenoy FJ. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 42: 1150–1156, 2003.
30. 2 entry. Circ Res 87: 551–557, 2000.
31. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277: 41128–41139, 2002.
32. Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82: 27–44, 2004.
33. Michel F, Simonet S, Vayssettes-Courchay C, Bertin F, Sansilvestri-Morel P, Bernhardt F, Paysant J, Silvestre JS, Levy BI, Félétou M, Verbeuren TJ. Altered TP receptor function in isolated, perfused kidneys of nondiabetic, and diabetic ApoE-deficient mice. Am J Physiol Renal Physiol 294: F120–F129, 2008.
34. Mitsutake S, Tani M, Okino N, Mori K, Ichinose S, Omori A, Iida H, Nakamura T, Ito M. Purification, characterization, molecular cloning, and subcellular distribution of neutral ceramidase of rat kidney. J Biol Chem 276: 26249–26259, 2001.
35. 2 elevation. FEBS Lett 579: 393–397, 2005.
36. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. Effects of sphingomyelinase, and sphingosine on arterial vasomotor regulation. J Lipid Res 37: 1601–1608, 1996.
37. Nagappan AS, Varghese J, Pranesh GT, Jeyaseelan V, Jacob M. Indomethacin inhibits activation of endothelial nitric oxide synthase in the rat kidney: possible role of this effect in the pathogenesis of indomethacin induced renal damage. Chem Biol Interact 221: 77–87, 2014.
38. Ohanian J, Forman SP, Katzenberg G, Ohanian V. Endothelin-1 stimulates small artery VCAM-1 expression through p38MAPK-dependent neutral sphingomyelinase. J Vasc Res 49: 353–362, 2012.
39. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Am J Physiol Regul Integr Comp Physiol 273: R293–R300, 1997.
40. 2 receptors: where have you gone? Prostaglandins Other Lipid Mediat 60: 175–189, 2000.
41. Purdy KE, Arendshorst WJ. Iloprost inhibits inositol-1,4,5-trisphosphate-mediated calcium mobilization stimulated by angiotensin II in cultured preglomerular vascular smooth muscle cells. J Am Soc Nephrol 12: 19–28, 2001.
42. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47: 383–392, 2003.
43. Shayman JA. Sphingolipids. Kidney Int 58: 11–26, 2000.
44. Smith AR, Visioli F, Frei B, Hagen TM. Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide-activated phosphatase 2A. Aging Cell 5: 391–400, 2006.
45. Spijkers LJ, van den Akker RF, Janssen BJ, Debets JJ, De Mey JG, Stroes ES, van den Born BJ, Wijesinghe DS, Chalfant CE, MacAleese L, Eijkel GB, Heeren RM, Alewijnse AE, Peters SL. Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide. PLoS One 6: e21817, 2011.
46. Spijkers LJ, Janssen BJ, Nelissen J, Meens MJ, Wijesinghe D, Chalfant CE, De Mey JG, Alewijnse AE, Peters SL. Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats. PLoS One 6: e29222, 2011.
47. Sugita M, Willians M, Dulaney JT, Moser HW. Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta 398: 125–131, 1975.
48. Walters MJ, Wrenn SP. Size-selective uptake of colloidal low density lipoprotein aggregates by cultured white blood cells. J Colloid Interface Sci 350: 494–501, 2010.
49. Wheal AJ, Alexander SP, Randall MD. Vasorelaxation to N-leoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity. Br J Pharmacol 160: 701–711, 2010.
50. Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 40: 1090–1097, 1991.
51. Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens 3: 242–249, 1990.
52. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913–R935, 2005.
53. Zador IZ, Deshmukh GD, Kunkel R, Johnson K, Radin NS, Shayman JA. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 91: 797–803, 1993.
54. Zager RA, Burkhart KM, Johnson A. Sphingomyelinase and membrane sphingomyelin content: determinants of proximal tubule cell susceptibility to injury. J Am Soc Nephrol 11: 894–902, 2000.
55. Zhang DX, Zou AP, Li PL. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res 88: 824–831, 2001.
56. Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase, and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 284: H605–H612, 2003.
57. 2]i in canine cerebral vascular muscle. Am J Physiol Heart Circ Physiol 278: H1421–H1428, 2000.
58. 2 mobilization in rat aortic smooth muscle. Eur J Pharmacol 391: 127–135, 2000.